Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma

NCT01804374 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

NETWORK

Sponsor class

Conditions

Metastatic Osteosarcoma
Relapsed Osteosarcoma

Interventions

DRUG: Sorafenib
DRUG: Everolimus

Sponsor

Italian Sarcoma Group